<DOC>
	<DOCNO>NCT01391871</DOCNO>
	<brief_summary>The purpose study compare vascular healing stented segment deployment new PRO-Kinetic drug elute stent Endeavor Resolute zotarolimus-eluting stent patient acute coronary syndrome require percutaneous coronary intervention .</brief_summary>
	<brief_title>Vascular Healing DES 3 Months</brief_title>
	<detailed_description>Objective : The aim trial compare vascular heal vasodilation 3 month deployment PRO-Kinetic drug-eluting stent Endeavor Resolute zotarolimus-eluting stent patient acute coronary syndrome . Design : A prospective , randomize control study compare coronary flow reserve coverage PRO-Kinetic DES Endeavor Resolute DES implant acute coronary syndrome . OCT CFR measurement 3 month . Clinical follow schedule 3 , 6 12 month . Primary endpoint : Uncovered stent strut CFR 3 month stent implantation . Secondary clinical endpoint : MACE stent thrombosis . Enrollment : 40 patient ( 20 receive PRO-Kinetic DES 20 receive Endeavor Resolute DES ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>STEMI NSTEMI unstable angina Patient legally authorize representative inform nature study , agree provision provide write informed consent , approve appropriate Medical Ethics committee Institutional Review Board . Single de novo nonstented restenosis lesion LAD Patients twovessel disease may undergo successful treatment nontarget vessel approve device include index procedure must treat prior index target vessel treatment . Target lesion ( maximum 20 mm length visual estimate ) cover single stent maximum 23mm length . Reference vessel diameter must &gt; 2.5mm &lt; 4.0mm visual estimate . The vessel diameter measure predilation procedure intracoronary nitroglycerin vasospasm suspect . Target lesion &gt; 50 % &lt; 100 % stenosed visual estimate . Preexisting diagnosis diabetes irrespective type . Impaired renal function ( serum creatinine &gt; 177micromol/l ) dialysis Platelet count &lt; 10 e5 cells/mm3 Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulation therapy contraindicate . Patient receive organ transplant wait list organ transplant . Patient known hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/prasugrel , stainless steel alloy , contrast agent adequately premedicated . Patient present cardiogenic shock . Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study . Currently participate another investigational drug device study . Unprotected leave main disease . Ostial target lesion . Chronic total occlusion . Calcified target lesion adequately predilated . Target lesion excessive tortuosity unsuitable stent delivery deployment . Target lesion involve bifurcation side branch large 2.0mm diameter . A &gt; 30 % stenosis proximal distal target lesion cover stent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>